• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
【24h】

Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.

机译：肌内齐拉西酮：在精神分裂症的急性躁动治疗中超越常规。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The appropriate management of schizophrenia and schizoaffective disorder requires effective, safe antipsychotic agents for use across a continuum of treatment, from control of acute psychotic episodes to prevention of relapse. Intramuscular (IM) formulations are the method of choice for administering antipsychotics to schizophrenic patients who require emergency treatment but cannot take oral medication. Atypical antipsychotics are now widely acknowledged as the first-line choice for the management of patients with schizophrenia. However, use of these agents in acutely agitated psychotic patients has been limited by the lack of an IM formulation. Ziprasidone is the first, and currently only, atypical antipsychotic to be available in a rapid-acting IM formulation. This review focuses on studies evaluating the efficacy and tolerability of IM ziprasidone. In agitated psychotic patients, IM ziprasidone reduces agitation as early as 15 minutes after administration, with improvement sustained for > or = 4 hours. In patients with acute psychosis, with or without agitation, IM ziprasidone has been demonstrated to be superior to IM haloperidol in improving overall symptom severity. During the critical IM-to-oral transition, efficacy and tolerability are maintained with ziprasidone. IM ziprasidone represents an important advance over older, conventional IM agents in the treatment of the acutely ill patient with schizophrenia.
机译：从控制急性精神病发作到预防复发，对精神分裂症和精神分裂症的适当管理需要有效，安全的抗精神病药，用于整个治疗过程。肌内（IM）制剂是向需要紧急治疗但不能口服药物的精神分裂症患者服用抗精神病药的首选方法。非典型抗精神病药现已被广泛认为是治疗精神分裂症患者的首选药物。但是，由于缺乏IM制剂，在精神激动性精神病患者中使用这些药物受到了限制。 Ziprasidone是第一种（也是目前唯一的）一种可在速效IM制剂中使用的非典型抗精神病药。这篇综述专注于评估IM齐拉西酮的疗效和耐受性的研究。在精神病性躁狂患者中，IM齐拉西酮最早可在给药后15分钟降低躁动，持续改善时间≥4小时。在急性精神病患者中，无论是否激动，IM齐拉西酮在改善总体症状严重程度方面均优于IM氟哌啶醇。在关键的IM到口腔过渡期间，齐拉西酮可维持疗效和耐受性。 IM齐拉西酮在治疗精神分裂症急性病患者方面比传统的IM药物具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号